Skip to main content

Lupus (Systemic Lupus Erythematosus) and cannabis in Minnesota

The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Not on the qualifying list
✗ No
LEGAL
30-day supply as certif…
POSSESSION
$40/yr
STATE FEE
7–30 d
TIMELINE
Not on the qualifying list. The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Minnesota statute and program

The Minnesota Medical Cannabis Program is the operating authority for Minnesota patient certification. The authoritative legal text is: Minnesota Statutes Chapter 342: Cannabis Regulation (HF 100 of 2023).

What the evidence says about cannabis and Lupus (Systemic Lupus Erythematosus)

Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disease in which the immune system produces autoantibodies that attack the body's own tissues. Inflammation can affect joints, skin, kidneys, blood, lungs, heart, and the nervous system. Lupus is a relapsing-remitting disease — patients experience flares and periods of relative quiescence.

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Lupus (Systemic Lupus Erythematosus) page.

How to qualify in Minnesota

The Minnesota Medical Cannabis Program requires the following registration steps for a Lupus (Systemic Lupus Erythematosus) patient (or any qualifying diagnosis):

  1. Get a written certification from a Minnesota-licensed practitioner. Under Minn. Stat. §152.22 et seq. (the Medical Cannabis Therapeutic Research Act of 2014, expanded under the 2023 cannabis reform), any Minnesota-licensed physician, advanced practice registered nurse, or physician assistant authorized to prescribe controlled substances may certify a patient. Qualifying conditions include cancer, glaucoma, HIV/AIDS, ALS, MS, seizures, intractable pain, IBD, autism spectrum, obstructive sleep apnea, terminal illness, PTSD, sickle-cell disease, Alzheimer’s, and others under §152.22(14).
  2. Apply through the Office of Cannabis Management portal. The certifying practitioner submits the written certification electronically to the Minnesota Office of Cannabis Management (OCM). The patient then completes the online patient enrollment with a Minnesota driver license or state ID, a passport-style photograph, and proof of Minnesota residency.
  3. Pay the $40 state enrollment fee (or $20 reduced fee). The annual Minnesota medical cannabis patient enrollment fee is $40, reduced to $20 for patients enrolled in MinnesotaCare, MA, SSI, or SSDI. The fee covers both the patient and any designated caregivers. Patients receive a digital patient enrollment confirmation through the OCM portal.
  4. Purchase from a Minnesota medical cannabis distribution location. With the OCM patient enrollment confirmation and a Minnesota ID, patients may purchase from any of the licensed Minnesota medical cannabis distribution locations (operated by the two medical cannabis manufacturers Vireo Health / Green Goods and LeafLine Labs / Rise). Permitted forms include flower (added 2022), capsules, tinctures, topicals, and vape products. Adult-use retail is expected to launch in late 2025 under the 2023 reform; medical patients retain reduced taxation and prioritized inventory.
State registration fee
$40
Physician visit (typical)
$150–$300
Certification to card
7–30 days
Out-of-state patients
Not eligible
Minors
Eligible with caregiver

For full Minnesota registration steps, fees, and reciprocity rules, see the Minnesota cannabis-laws page.

ICD-10 code

A certifying physician documenting Lupus (Systemic Lupus Erythematosus) for the Minnesota medical cannabis program will typically record ICD-10 M32.9 or SNOMED-CT 55464009 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does Minnesota list Lupus (Systemic Lupus Erythematosus) as a qualifying condition for medical cannabis?

No. Minnesota's qualifying-condition list does not currently include Lupus (Systemic Lupus Erythematosus), and the state's program does not give physicians open-ended discretion to add conditions outside the list. Patients with Lupus (Systemic Lupus Erythematosus) in Minnesota have limited in-state pathways under the medical program as written. Options to verify and pursue include: petitioning the state regulator to add the condition (where the statute permits public petitions); consulting a physician about whether a co-occurring listed condition could support certification; or reviewing whether the state's program is undergoing legislative expansion. Minnesota program rules change, so verify the current list with the regulator before drawing a final conclusion.

How do I get a Minnesota medical marijuana card for Lupus (Systemic Lupus Erythematosus)?

Because Minnesota does not currently list Lupus (Systemic Lupus Erythematosus) as a qualifying condition, a card for Lupus (Systemic Lupus Erythematosus) alone may not be obtainable in-state under the program rules as written. Step one is finding a physician licensed in Minnesota who is registered with Minnesota Medical Cannabis Program and willing to evaluate Lupus (Systemic Lupus Erythematosus) cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Minnesota does not honor out-of-state cards, so the certification process has to originate inside the state. Verify the patient minimum age with the state program before applying. Confirm the current process with the state regulator before applying, because the rules change.

What does the evidence say about cannabis for Lupus (Systemic Lupus Erythematosus)?

For Lupus (Systemic Lupus Erythematosus), evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Lupus (Systemic Lupus Erythematosus) lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Lupus (Systemic Lupus Erythematosus) should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Lupus (Systemic Lupus Erythematosus) and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Lupus (Systemic Lupus Erythematosus); the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. Minnesota Statutes Chapter 342: Cannabis Regulation (HF 100 of 2023)accessed May 15, 2026
  2. Minnesota Office of Cannabis Managementaccessed May 15, 2026
  3. NORML: Minnesota Lawsaccessed May 15, 2026
  4. NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases: Lupusaccessed May 18, 2026
  5. NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 18, 2026

    “Substantial evidence that cannabis or cannabinoids are effective for chronic pain in adults.”

  6. Lupus Foundation of America: Marijuana and Lupusaccessed May 18, 2026
  7. American College of Rheumatology: 2023 Guideline for SLE Management (executive summary)accessed May 18, 2026
  8. MedlinePlus: Systemic lupus erythematosusaccessed May 18, 2026